Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2024-05-29 Regulatory Filings
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
ORYZON es seleccionada como Miembro Asociado en el primer Proyecto Importante de Interés Común Europeo (PIICE) en el sector de la salud (proyecto Med4Cure)
Regulatory Filings Classification · 100% confidence The document is a formal communication from ORYZON GENOMICS, S.A. titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information), dated May 29, 2024. It announces that the company has been selected to participate in a major European project (IPCEI/PIICE) in the health sector and explicitly states: 'Se adjunta como anexo la nota de prensa que será distribuida en el día de hoy' (The press release to be distributed today is attached as an annex). The body of the text is essentially that press release detailing the selection and the project scope. Since this is an announcement about a significant corporate event (participation in a major EU project) and it explicitly mentions attaching/distributing a press release, it functions as a general regulatory disclosure or an announcement of material information. Given the options, this type of disclosure, which is not a standard periodic report (10-K, IR, ER) but rather a specific, material corporate update often mandated by market regulators (indicated by the reference to Article 227 of the Spanish Securities Market Law), fits best under the general 'Regulatory Filings' category (RNS) or potentially an 'Other' category if RNS is reserved strictly for non-specific filings. Since it is a specific, material announcement that doesn't fit ER, CT, or CAP precisely, RNS (Regulatory Filings / Miscellaneous) is the most appropriate fallback for non-standard, material corporate news releases.
2024-05-29 Spanish
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S.A.
AGM Information Classification · 99% confidence The document is an official announcement titled "CONVOCATORIA DE LA JUNTA GENERAL ORDINARIA DE ACCIONISTAS 2024 DE ORYZON GENOMICS, S.A." (Call for the 2024 Annual General Shareholders' Meeting). It details the date, time, location, and the full Order of the Day for the meeting, which includes approving the 2023 annual accounts and management, appointing auditors, and proposing a capital increase. This content directly relates to the formal procedures and materials associated with an Annual General Meeting (AGM). Although it includes details about voting rights and documentation access, the primary purpose is the formal convocation of the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2024-05-27 Spanish
La sociedad comunica la conversión de obligaciones convertibles
Capital/Financing Update Classification · 98% confidence The document is a formal communication from ORYZON GENOMICS, S.A. titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It explicitly details a conversion of convertible bonds into new ordinary shares, resulting in an increase of the company's share capital ('aumentar su capital social'). This action directly relates to changes in the company's capital structure and financing instruments. Based on the definitions, this fits best under 'Capital/Financing Update' (CAP), as it reports on the execution of a financing program (convertible obligations) leading to a capital increase.
2024-05-17 Spanish
La Sociedad remite información sobre los resultados del primer trimestre de 2024
Earnings Release Classification · 99% confidence The document is explicitly titled 'NOTA DE RESULTADOS: PRIMER TRIMESTRE DE 2024' (Results Note: First Quarter of 2024) and contains detailed financial tables for the 'CUENTA DE RESULTADOS DEL PRIMER TRIMESTRE DE 2024' (Income Statement for the First Quarter of 2024) and the balance sheet as of March 31, 2024. This content strongly indicates a periodic financial report covering a period shorter than a year. The document also mentions it is a 'nota de prensa' (press release) announcing these results, but the inclusion of full, detailed financial statements (tables with line items and comparative periods) elevates it beyond a simple Earnings Release (ER) which typically only contains highlights. It fits the definition of a comprehensive financial report for a shorter period, which corresponds to the Interim / Quarterly Report (IR) category. Although it is presented as a press release, the substance is the quarterly report itself. Q1 2024
2024-05-06 Spanish
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2023
Remuneration Information Classification · 100% confidence The document text explicitly discusses the 'Política de Remuneraciones de la Sociedad' (Company Remuneration Policy) for directors ('consejeros') for the current fiscal year (2023, 2024, 2025). It details fixed and variable components, risk mitigation measures, long-term incentive plans, and governance related to executive compensation. This content directly aligns with the definition of a Remuneration Information report, which corresponds to the DEF 14A filing type in the US context, or similar detailed compensation disclosures required by various jurisdictions, matching the provided code 'DEF 14A'. The document is comprehensive and detailed, not a mere announcement of a report.
2024-02-26 Spanish
Corporate Governance Report - Oryzon Genomics S.A.
Remuneration Information Classification · 100% confidence The document text explicitly discusses the 'Política de Remuneraciones de la Sociedad' (Company Remuneration Policy) for directors ('consejeros') for the current fiscal year (2023, 2024, 2025). It details fixed and variable components, risk mitigation measures, long-term incentive plans, and governance related to executive compensation. This content directly aligns with the definition of a Remuneration Information report, which corresponds to the DEF 14A filing type in the US context, or similar detailed compensation disclosures required by various jurisdictions, matching the provided code 'DEF 14A'. The document is comprehensive and detailed, not a mere announcement of a report.
2024-02-26 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.